S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
HALO · Halozyme Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Halozyme Therapeutics Inc (HALO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$124.86
+0.55
(+0.44%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$124.86
$123.05
$125.34
52-WEEK RANGE
$124.86
$61.23
$125.10
What's happening
- HALO is up 0.44% today, trading at $124.86. — Live quote
- It's trading within 3% of its 52-week high ($125.10). (Finnhub fundamentals)
- Volume today (78,473) is well below its 3-month average of 2,151,140. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $2.28 actual vs. $1.87 estimated (+21.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 10
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
HALO
+84.80%
vs S&P 500
+72.02%
1-YEAR RETURN
HALO
+87.11%
vs S&P 500
+72.55%
6-MONTH RETURN
HALO
+86.63%
3-MONTH RETURN
HALO
+58.23%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$2.28
Est. $1.87
BEAT +21.7%
2026-04-26 (Q1 2026)
$1.60
Est. $1.56
BEAT +2.5%
2026-01-26 (Q4 2025)
$-0.24
Est. $2.24
MISS -110.7%
2025-10-26 (Q3 2025)
$1.72
Est. $1.66
BEAT +3.6%
Valuation Measures & Ratios
Enterprise Value4$16.16B
Forward P/E511.43
PEG Ratio61.08
Price / Sales (TTM1)8.52
Price / Book764.68
EV4 / Revenue9.71
EV4 / EBITDA23.36
Profit Margin24.86%
Operating Margin35.57%
Return on Equity (ROE8)180.63%
Return on Assets (ROA9)16.55%
Avg Volume (3M)2,151,140
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $9.47B | $7.95B | $8.98B | $6.46B | $8.10B |
| P/E | 13.15 | 13.06 | 15.08 | 12.58 | 19.05 |
| Price/Sales | 6.16 | 6.01 | 7.27 | 5.81 | 8.25 |
| Price/Book | 65.97 | 36.18 | 17.82 | 19.42 | 16.80 |
| EV/Revenue | 7.45 | 7.40 | 8.16 | 7.11 | 9.60 |
| EV/EBITDA | 12.63 | 12.89 | 13.69 | — | — |
| ROE | 501.83% | 277.06% | 118.17% | 154.32% | 88.16% |
| ROA | 27.95% | 22.77% | 26.81% | 25.00% | 19.36% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short15,295,841
Change from Prior Settlement+0.93%
% of Float—
Days to Cover (Short Ratio)4.54
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 47.7% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 24.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is +87.1%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-08; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on HALO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $481.0M | $376.7M | $354.3M | $325.7M | $264.9M | $290.1M | $231.4M | $195.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $287.7M | $184.5M | $217.9M | $202.4M | $141.5M | $163.2M | $117.2M | $95.5M |
| Net income | $229.9M | $150.0M | $175.2M | $165.2M | $118.1M | $137.0M | $93.2M | $76.8M |
| EPS (diluted) | $1.90 | $1.22 | $1.43 | $1.33 | $0.93 | $1.05 | $0.72 | $0.60 |
| EPS (basic) | $1.96 | $1.27 | $1.49 | $1.36 | $0.96 | $1.08 | $0.73 | $0.61 |
| Operating margin | $60 | $49 | $62 | $62 | $53 | $56 | $51 | $49 |
| Net margin | $48 | $40 | $49 | $51 | $45 | $47 | $40 | $39 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $2.58B | $2.67B | $2.53B | $2.22B | $2.05B | $2.20B | $2.06B | $2.12B |
| Total liabilities | $2.43B | $2.45B | $2.48B | $1.72B | $1.72B | $1.71B | $1.70B | $1.67B |
| Stockholders' equity | $143.5M | $219.6M | $48.8M | $503.9M | $332.7M | $482.3M | $363.8M | $452.7M |
| Total current assets | $933.0M | $1.00B | $825.2M | $1.33B | $1.12B | $1.26B | $1.09B | $1.13B |
| Total current liabilities | $344.4M | $363.2M | $177.1M | $837.2M | $134.3M | $150.4M | $139.1M | $108.8M |
| Cash & equivalents | $163.1M | $309.7M | $133.8M | $419.7M | $61.9M | $176.3M | $115.8M | $154.3M |
| Accounts receivable | $453.3M | $458.0M | $426.3M | $343.5M | $315.1M | $304.0M | $288.2M | $273.1M |
| Inventory | $137.1M | $155.5M | $176.5M | $185.8M | $181.5M | $164.9M | $141.9M | $131.4M |
| Property, plant & equipment | $49.8M | $46.9M | $44.4M | $40.6M | $39.6M | $40.2M | $40.9M | $40.0M |
| Goodwill | $581.7M | $582.3M | $580.4M | $416.8M | $416.8M | $416.8M | $416.8M | $416.8M |
| Intangible assets | $922.4M | $952.0M | $981.5M | $348.5M | $366.3M | $384.1M | $401.8M | $419.6M |
| Accounts payable | $23.6M | $14.1M | $20.9M | $15.4M | $18.7M | $20.1M | $10.2M | $12.4M |
| Accrued liabilities | $111.9M | $140.4M | $156.2M | $111.2M | $115.6M | $130.3M | $128.9M | $96.4M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | $209.0M | $208.7M | $0 | $710.7M | — | — | $0 | — |
| Long-term debt | $1.94B | $1.94B | $2.14B | $800.1M | $1.51B | $1.51B | $1.51B | $1.50B |
| Other non-current liabilities | $102.7M | $106.4M | $113.9M | $71.8M | $77.8M | $56.4M | $54.8M | $40.4M |
| Common stock & paid-in capital | $114.0K | $118.0K | $118.0K | $118.0K | $118.0K | $123.0K | $123.0K | $127.0K |
| Retained earnings | $151.3M | $204.8M | $54.8M | $502.1M | $361.0M | $478.0M | $359.9M | $397.6M |
| Accumulated other comprehensive income (loss) | -$7.8M | -$12.7M | -$18.1M | -$22.3M | -$28.4M | -$3.4M | $3.8M | -$6.9M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $240.9M | $180.1M | $219.0M | $178.6M | $99.7M | $154.2M | $178.5M | $115.4M |
| Investing cash flow | -$62.7M | -$2.9M | -$741.8M | $201.6M | $84.8M | -$90.4M | $29.5M | -$167.5M |
| Financing cash flow | -$326.3M | -$1.6M | $239.5M | -$22.4M | -$299.0M | -$3.3M | -$246.4M | $18.6M |
| Free cash flow | $236.7M | $176.3M | $217.6M | $175.6M | $98.1M | $153.3M | $175.4M | $113.9M |
| Capital expenditures | $4.2M | $3.7M | $1.4M | $3.0M | $1.6M | $950.0K | $3.1M | $1.5M |
| Depreciation & amortization | $4.5M | $4.2M | $8.7M | $2.7M | $2.7M | $2.7M | $7.8M | $2.6M |
| Share-based compensation | $17.7M | $16.6M | $16.6M | $12.2M | $12.2M | $10.7M | $11.5M | $12.6M |
| Change in accounts receivable | -$2.2M | $19.5M | $90.5M | $29.7M | $11.7M | -$3.8M | $22.7M | $71.2M |
| Change in inventory | -$18.3M | -$27.4M | -$18.8M | $1.1M | $14.5M | $586.0K | $7.7M | -$2.0M |
| Purchases of investments | $111.8M | $8.8M | $0 | $5.0M | $102.8M | $139.6M | $51.4M | $304.0M |
| Sales/maturities of investments | $53.3M | $9.0M | — | $209.6M | $189.1M | $50.2M | — | $138.0M |
| Share repurchases | $332.7M | — | $0 | $38.9M | $303.5M | — | $250.0M | $0 |
| Tax withholding on stock comp | — | $1.6M | — | — | — | $3.3M | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M | $443.3M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M |
| EPS (diluted) | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 |
| EPS (basic) | $2.64 | $3.50 | $2.13 | $1.48 | $2.86 |
| Operating margin | $34 | $54 | $41 | $41 | $62 |
| Net margin | $23 | $44 | $34 | $31 | $91 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B |
| Total liabilities | $2.48B | $1.70B | $1.65B | $1.67B | — |
| Stockholders' equity | $48.8M | $363.8M | $83.8M | $169.8M | $197.0M |
| Total current assets | $825.2M | $1.09B | $746.4M | $739.0M | $926.3M |
| Total current liabilities | $177.1M | $139.1M | $112.5M | $130.8M | $117.1M |
| Cash & equivalents | $133.8M | $115.8M | $118.4M | $234.2M | $118.7M |
| Accounts receivable | $426.3M | $288.2M | $233.3M | $231.1M | $91.0M |
| Inventory | $176.5M | $141.9M | $127.6M | $100.1M | $53.9M |
| Property, plant & equipment | $44.4M | $40.9M | $38.1M | $35.1M | $6.8M |
| Goodwill | $580.4M | $416.8M | $416.8M | $409.0M | $0 |
| Intangible assets | $981.5M | $401.8M | $472.9M | $546.7M | $0 |
| Accounts payable | $20.9M | $10.2M | $11.8M | $17.7M | $1.5M |
| Accrued liabilities | $156.2M | $128.9M | $100.7M | $99.8M | $24.4M |
| Deferred revenue (current) | — | — | — | $3.2M | $1.7M |
| Short-term debt | $0 | $0 | $0 | $13.3M | $89.4M |
| Long-term debt | $2.14B | $1.51B | $1.50B | $1.49B | $787.3M |
| Other non-current liabilities | $113.9M | $54.8M | $37.7M | $32.7M | $544.0K |
| Common stock & paid-in capital | $118.0K | $123.0K | $127.0K | $135.0K | $138.0K |
| Retained earnings | $54.8M | $359.9M | $90.5M | $143.2M | -$58.9M |
| Accumulated other comprehensive income (loss) | -$18.1M | $3.8M | -$9.3M | -$922.0K | -$620.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M |
| Investing cash flow | -$545.8M | -$262.7M | -$96.9M | -$487.0M | -$406.3M |
| Financing cash flow | -$85.2M | -$218.9M | -$408.0M | $362.4M | $77.9M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M | $298.0M |
| Capital expenditures | $7.0M | $10.7M | $15.3M | $4.8M | $1.5M |
| Depreciation & amortization | $11.4M | $10.3M | $11.1M | $6.5M | $3.0M |
| Share-based compensation | $51.6M | $43.4M | $36.6M | $24.4M | $20.8M |
| Change in accounts receivable | $128.1M | $74.2M | $3.3M | $83.9M | -$6.8M |
| Change in inventory | -$2.6M | $67.4M | $26.9M | $17.5M | -$7.4M |
| Purchases of investments | $247.4M | $647.6M | $292.9M | $255.2M | $652.5M |
| Sales/maturities of investments | — | — | — | $746.1M | $247.7M |
| Share repurchases | $342.4M | $250.0M | $402.4M | $200.0M | $350.1M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding HALO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-06 to 2026-10-08
Recent transactions
- Insiders have net sold 319,954 shares over the last 182 days, across 0 purchases and 67 sales.
- Most recent: Torley Helen (PRESIDENT AND CEO) — Option exercise of 20,000 shares on 2026-10-08.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)319,954 sh(67 txns)
Net Shares-319,954
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO | Option exercise | 2026-10-08 | 20,000 |
| Daly James M | Director | Grant / award | 2026-10-01 | 1,169 |
| Posard Matthew L. | Director | Open market sale | 2026-10-01 | 730 |
| Appelhans Dannielle | Director | Grant / award | 2026-09-01 | 1,161 |
| Connaughton Bernadette | Director | Open market sale | 2026-08-10 | 1,626 |
| RAMSAY DAVID A | EVP, PRESIDENT, DRUG DELIVERY | Option exercise | 2026-06-30 | 10,000 |
| Krishnan Mahesh | Director | Option exercise | 2026-06-29 | 7,304 |
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | Option exercise | 2026-06-12 | 5,034 |
| Lang James Paul | Director | Grant / award | 2026-05-05 | 3,796 |
| Henderson Jeffrey William | Director | Grant / award | 2026-05-05 | 3,796 |
| DUNCAN BARBARA GAYLE | Director | Grant / award | 2026-05-05 | 3,796 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-08 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20,000 | $18.41 |
| 2026-10-08 | Torley Helen | PRESIDENT AND CEO | Open market sale | 4,810 | $108.18 |
| 2026-10-08 | Torley Helen | PRESIDENT AND CEO | Open market sale | 3,090 | $108.91 |
| 2026-10-08 | Torley Helen | PRESIDENT AND CEO | Open market sale | 11,900 | $110.00 |
| 2026-10-08 | Torley Helen | PRESIDENT AND CEO | Open market sale | 200 | $110.51 |
| 2026-10-07 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20,000 | $18.41 |
| 2026-10-07 | Torley Helen | PRESIDENT AND CEO | Open market sale | 8,600 | $111.03 |
| 2026-10-07 | Torley Helen | PRESIDENT AND CEO | Open market sale | 10,300 | $111.84 |
| 2026-10-07 | Torley Helen | PRESIDENT AND CEO | Open market sale | 900 | $112.78 |
| 2026-10-07 | Torley Helen | PRESIDENT AND CEO | Open market sale | 200 | $113.69 |
| 2026-10-06 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20,000 | $18.41 |
| 2026-10-06 | Torley Helen | PRESIDENT AND CEO | Open market sale | 2,300 | $107.90 |
| 2026-10-06 | Torley Helen | PRESIDENT AND CEO | Open market sale | 6,000 | $109.33 |
| 2026-10-06 | Torley Helen | PRESIDENT AND CEO | Open market sale | 9,920 | $109.89 |
| 2026-10-06 | Torley Helen | PRESIDENT AND CEO | Open market sale | 1,780 | $110.81 |
| 2026-10-01 | Daly James M | Director | Grant / award | 1,169 | $0.00 |
| 2026-10-01 | Posard Matthew L. | Director | Open market sale | 730 | $107.17 |
| 2026-10-01 | Posard Matthew L. | Director | Open market sale | 3,300 | $108.45 |
| 2026-10-01 | Posard Matthew L. | Director | Open market sale | 1,100 | $109.57 |
| 2026-10-01 | Posard Matthew L. | Director | Open market sale | 100 | $110.04 |
| 2026-09-16 | Posard Matthew L. | Director | Open market sale | 3,100 | $106.13 |
| 2026-09-16 | Posard Matthew L. | Director | Open market sale | 3,000 | $106.83 |
| 2026-09-16 | Posard Matthew L. | Director | Open market sale | 8,896 | $108.04 |
| 2026-09-16 | Posard Matthew L. | Director | Open market sale | 4,000 | $108.99 |
| 2026-09-11 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20,000 | $18.41 |
| 2026-09-11 | Torley Helen | PRESIDENT AND CEO | Open market sale | 15,492 | $107.15 |
| 2026-09-11 | Torley Helen | PRESIDENT AND CEO | Open market sale | 4,508 | $107.55 |
| 2026-09-10 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20,000 | $18.41 |
| 2026-09-10 | Torley Helen | PRESIDENT AND CEO | Open market sale | 14,588 | $107.01 |
| 2026-09-10 | Torley Helen | PRESIDENT AND CEO | Open market sale | 5,412 | $107.58 |
| 2026-09-09 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20,000 | $18.41 |
| 2026-09-09 | Torley Helen | PRESIDENT AND CEO | Open market sale | 13,304 | $107.22 |
| 2026-09-09 | Torley Helen | PRESIDENT AND CEO | Open market sale | 6,596 | $107.82 |
| 2026-09-09 | Torley Helen | PRESIDENT AND CEO | Open market sale | 100 | $108.67 |
| 2026-09-01 | Appelhans Dannielle | Director | Grant / award | 1,161 | $0.00 |
| 2026-08-19 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20,000 | $18.41 |
| 2026-08-19 | Torley Helen | PRESIDENT AND CEO | Open market sale | 7,200 | $106.36 |
| 2026-08-19 | Torley Helen | PRESIDENT AND CEO | Open market sale | 9,600 | $107.22 |
| 2026-08-19 | Torley Helen | PRESIDENT AND CEO | Open market sale | 3,200 | $107.77 |
| 2026-08-18 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20,000 | $18.41 |
| 2026-08-18 | Torley Helen | PRESIDENT AND CEO | Open market sale | 5,703 | $103.08 |
| 2026-08-18 | Torley Helen | PRESIDENT AND CEO | Open market sale | 4,897 | $104.11 |
| 2026-08-18 | Torley Helen | PRESIDENT AND CEO | Open market sale | 9,400 | $104.87 |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20,000 | $18.41 |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Open market sale | 900 | $98.96 |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Open market sale | 500 | $100.46 |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Open market sale | 2,100 | $101.77 |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Open market sale | 9,000 | $102.55 |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Open market sale | 7,500 | $103.48 |
| 2026-08-10 | Connaughton Bernadette | Director | Open market sale | 1,626 | $102.80 |
| 2026-07-08 | Torley Helen | PRESIDENT AND CEO | Option exercise | 1,923 | $12.07 |
| 2026-07-08 | Torley Helen | PRESIDENT AND CEO | Open market sale | 888 | $79.28 |
| 2026-07-08 | Torley Helen | PRESIDENT AND CEO | Open market sale | 1,035 | $80.19 |
| 2026-07-01 | Connaughton Bernadette | Director | Open market sale | 1,000 | $76.39 |
| 2026-07-01 | Connaughton Bernadette | Director | Open market sale | 625 | $77.21 |
| 2026-06-30 | RAMSAY DAVID A | EVP, PRESIDENT, DRUG DELIVERY | Option exercise | 10,000 | $0.00 |
| 2026-06-30 | RAMSAY DAVID A | EVP, PRESIDENT, DRUG DELIVERY | Tax withholding | 5,408 | $78.27 |
| 2026-06-29 | Krishnan Mahesh | Director | Option exercise | 7,304 | $38.46 |
| 2026-06-29 | Krishnan Mahesh | Director | Open market sale | 7,304 | $75.00 |
| 2026-06-12 | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | Option exercise | 5,034 | $0.00 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:11 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-08 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-30 | 8-K | 2026-09-28 | View on SEC.gov → |
| 2026-09-22 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-09-18 | 8-K | 2026-09-17 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-16 | 8-K | 2026-09-16 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 8-K | 2026-08-14 | View on SEC.gov → |
Recent news
Headlines about HALO (Halozyme Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts
Yahoo Finance · 2026-10-21 -
5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings
Yahoo · 2026-10-21 -
ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook
Yahoo · 2026-10-21 -
Halozyme’s Strong Earnings Growth Sends Shares Higher
FXEmpire · 2026-10-21 -
HALO Dec 2027 140.000 call (HALO271217C00140000) interactive stock chart
Yahoo Finance UK · 2026-10-21 -
HALO Dec 2026 35.000 call (HALO261218C00035000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
HALO Dec 2026 110.000 put (HALO261218P00110000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
H.C. Wainwright reaffirms USD 130 target for Halozyme Therapeutics stock
AD HOC NEWS · 2026-10-20
No headlines in this category right now — try “All”.